| Identification | Back Directory | [Name]
AriMocloMol Maleic Acid | [CAS]
289893-26-1 | [Synonyms]
BRX220
BRX-220
BRX-345
BRX345.
BRX 220
BRX 345
AriMocloMol Maleic Acid
(2R)-Arimoclomol maleate
(2R)-Arimoclomol Maleic Acid
ARIMOCLOMOL MALEATE (BRX-220)
ARIMOCLOMOL MALEATE; BRX-220; BRX 220; BRX220; BRX-345; BRX 345; BRX345. | [Molecular Formula]
C18H24ClN3O7 | [MOL File]
289893-26-1.mol | [Molecular Weight]
429.852 |
| Chemical Properties | Back Directory | [Melting point ]
>131°C (dec.) | [storage temp. ]
Amber Vial, -20°C Freezer, Under inert atmosphere | [solubility ]
DMSO (Slightly), Methanol (Slightly) | [form ]
Solid | [color ]
White to Off-White | [Water Solubility ]
H2O: 2mg/mL, clear |
| Hazard Information | Back Directory | [Uses]
AriMocloMol Maleic Acid is a orally administered drug used to treat amyotrophic lateral sclerosis and was later discovered to be a potential insulin resistance treatment and diabetic complications.
| [Biological Activity]
Arimoclomol is an orally availableCNS-penetrant coinducer of he at shock proteins (HSPs)notably HSP70th at exhibits in vivo efficay in disease models of diabetesGaucher disease (GD)sporadic inclusion body myositis (sIBM)and neurological disordersincluding amyotrophic lateral sclerosis (ALS) and Niemann-Pick disease type C1 (NPC1). Note: arimoclomol maleate and citrate salt forms are known as BRX-220 and BRX-345respectively. | [in vivo]
Arimoclomol (BRX-220; 20 mg/kg; orally administered for 5 d) has a protective effect against cholecystokinin-octapeptide (CCK)-induced acute pancreatitis[1]. | Animal Model: | Male Wistar rats weighing 240 to 270 g[1] | | Dosage: | 20 mg/kg | | Administration: | Administered intragastrically, for 5 days | | Result: | Had a protective effect against CCK-induced acute pancreatitis. |
| [IC 50]
HSP | [storage]
Store at -20°C |
|
|